Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 15/20 | 0.68 |
| ▸ | MAPT | P10636 | 13/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 11/20 | 0.68 |
| ▸ | L3MBTL1 | Q9Y468 | 5/20 | 0.68 |
| ▸ | RAB9A | P51151 | 4/20 | 0.68 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.68 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 10/20 | 0.68 |
| ▸ | HPGD | P15428 | 9/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.58 |
| ▸ | HTT | P42858 | 5/20 | 0.58 |
| ▸ | LMNA | P02545 | 3/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.57 |
| ▸ | NPC1 | O15118 | 2/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | TP53 | P04637 | 2/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.52 |
| ▸ | CASP1 | P29466 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2251270 | 0.90 | GAA (0.68) | GAAMAPTALDH1A1L3MBTL1RAB9A | |
| SCHEMBL2253516 | 0.89 | GAA (0.74) | GAAMAPTALDH1A1L3MBTL1RAB9A | |
| SCHEMBL2252724 | 0.88 | GAA (0.75) | GAAMAPTALDH1A1L3MBTL1RAB9A | |
| SCHEMBL5374835 | 0.87 | MAPT (0.80) | GAAMAPTALDH1A1L3MBTL1RAB9A | |
| SCHEMBL2252198 | 0.86 | MAPT (0.78) | GAAMAPTALDH1A1L3MBTL1NPSR1 | |
| SCHEMBL2254234 | 0.84 | GAA (0.74) | GAAMAPTALDH1A1L3MBTL1RAB9A | |
| SCHEMBL2254201 | 0.83 | GAA (0.56) | GAAMAPTALDH1A1L3MBTL1RAB9A | |
| SCHEMBL2250303 | 0.78 | MAPT (0.53) | GAAMAPTALDH1A1L3MBTL1RAB9A | |
| SCHEMBL5370506 | 0.76 | GAA (0.80) | GAAMAPTALDH1A1L3MBTL1RAB9A | |
| SCHEMBL5425036 | 0.75 | NR1H4 (0.62) | GAAMAPTALDH1A1L3MBTL1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2155747-B1 | IMIDAZOL (1,2-A)PYRIDINES AND RELATED COMPOUNDS WITH ACTIVITY AT CANNABINOID CB2 RECEPTORS | GE HEALTHCARE LTD (GB) | 2012-10-24 | — | — | EP | disclosed |
| US-20110206607-A1 | IMIDAZOL (1,2-A)PYRIDINES AND RELATED COMPOUNDS WITH ACTIVITY AT CANNABINOID CB2 RECEPTORS | GE HEALTHCARE LIMITED (GB) | 2011-08-25 | — | — | US | disclosed |
| US-20110206607-A1 | IMIDAZOL (1,2-A)PYRIDINES AND RELATED COMPOUNDS WITH ACTIVITY AT CANNABINOID CB2 RECEPTORS | GE HEALTHCARE LIMITED (GB) | 2011-08-25 | — | — | US | disclosed |
| US-20110206607-A1 | IMIDAZOL (1,2-A)PYRIDINES AND RELATED COMPOUNDS WITH ACTIVITY AT CANNABINOID CB2 RECEPTORS | GE HEALTHCARE LIMITED (GB) | 2011-08-25 | — | — | US | disclosed |
| WO-2008141249-A1 | IMIDAZOL (1,2-A)PYRIDINES AND RELATED COMPOUNDS WITH ACTIVITY AT CANNABINOID CB2 RECEPTORS | ACADIA PHARMACEUTICALS INC. (US) | 2008-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110206607-A1 | IMIDAZOL (1,2-A)PYRIDINES AND RELATED COMPOUNDS WITH ACTIVITY AT CANNABINOID CB2 RECEPTORS | CNR1, CNR2, GPR18 | GAA 4087/4885MAPT 2915/4885ALDH1A1 3205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.